Compare Revvity Inc (RVTY) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs United States Natural Gas Fund — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while United States Natural Gas Fund trades at $11.01 (market cap $517.27M). The key difference: Revvity Inc is far larger — about 32.8× United States Natural Gas Fund's market cap, and Revvity Inc pays a 0.18% dividend while United States Natural Gas Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and United States Natural Gas Fund for 22 Days on average.
| RVTY | UNG | |
|---|---|---|
Market Cap | $16.98B | $517.27M |
Volume | 1,456,900 | 29,485,537 |
Sector | Health | Commodities - Energy |
52-Week High | $157.36 | $16.90 |
52-Week Low | $82.26 | $9.63 |
Typical Hold Time | 12 Days | 22 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
UNG trades at $10.81, down 1.99% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong net income of $65.15M for 2024 despite zero revenue, with robust cash flow from operations of $47.54M. Recent news highlights natural gas market volatility driven by record production and geopolitical tensions.
The outlook is mixed: technical momentum supports near-term upside, but fundamental concerns arise from zero revenue and negative net cash flow. Risks include commodity price sensitivity and geopolitical factors affecting natural gas markets. Analyst sentiment leans bullish on technicals but requires fundamental improvement for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
